We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Stanford University Genome Technology Center Advances Genetic Research and Development

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

BioTrove, Inc. has announced that the Stanford University Genome Technology Center will advance multiple research projects through the use of the BioTrove OpenArray™ technology platform.

Researchers in the Stanford Genome Technology lab, led by Professor Ronald Davis, Director, anticipate applications in single nucleotide polymorphism (SNP) genotyping, real-time quantitative polymerase chain reaction (PCR)-based tests, and the development of uses for the OpenArray system.

“One of the challenges facing academic research centers today is access to high-accuracy, cost-sensible technology that enables our students and professors to bring their projects to life,” said Ronald Davis.

“By increasing the number of reactions analyzed at one time by as much as ten-fold, and with the flexibility to use its technology in multiple applications, the OpenArray platform enables faster, more cost-effective analysis of biologic samples. We also look forward to exploring new ways to use the OpenArray plates in our research,” he added.

According to BioTrove, with OpenArray plates and the OpenArray NT Imager, researchers can generate up to 100,000 SNP genotypes per day, without the need for expensive robotics. With the OpenArray plates and NT Cycler system, researchers can generate as many as 9,216 real time PCR data points at one time.

“By engaging important biological questions with breakthrough technology, Stanford Genome Technology Center researchers continue to innovate and lead the way in many areas of research,” said Albert Luderer, Ph.D., president and CEO, BioTrove.

“As a company committed to advancing research that improves public health and quality-of-life, BioTrove is excited to enable this work,” Luderer continued.